New Insights into APOE4’s Role in Early Alzheimer’s Risks and Potential Therapeutic Targets

Recent findings from the Gladstone Institutes uncover how the APOE4 gene variant, a significant genetic risk factor for Alzheimer’s disease, begins to influence brain function long before cognitive decline becomes apparent. This research outlines a molecular pathway that not only elucidates these early changes but also suggests avenues for reversing some effects.

In a study published in Nature Aging, researchers conducted experiments using mouse models to dissect the early impacts of APOE4 on neuronal activity. They found that elevated levels of a protein named Nell2 were correlated with APOE4's presence, leading to smaller, hyperactive neurons. The most pronounced neuronal hyperactivity observed in young mice foreshadowed severe memory deficits in later stages of their lives.

By reducing the production of Nell2 in these model organisms, the research team observed a return of the neurons to their more typical size and firing patterns, pointing toward Nell2 as a promising target for future pharmacological interventions aimed at those genetically predisposed to Alzheimer’s.

Misha Zilberter, PhD, who led the study, emphasized, "To the best of our knowledge, this is the first study that has directly examined what APOE4 does to the function of neurons at different ages." He highlighted the unexpected finding that significant alterations in brain circuitry occur before any noticeable decline in learning and memory abilities, setting the stage for later cognitive impairments.

APOE4, one of three variants of the APOE gene, is carried by approximately one in four individuals. Alarmingly, it appears in 60 to 75 percent of people diagnosed with Alzheimer's. Yadong Huang, MD, PhD, who also contributed to this research, remarked on the study's implications: "It opens the door to a better understanding of how APOE4 alters the function of neurons at a young age to increase risk of cognitive decline." The identification of mechanisms that enable such a connection could guide the development of preventive therapies.

Prior inquiries have identified instances of heightened brain activity in human APOE4 carriers prior to midlife, linking this early hyperactivity to subsequent cognitive decline. However, the exact processes by which APOE4 induces these cellular transformations have been obscure until now.

In their investigation, researchers meticulously analyzed the brain activity recordings of young mice and observed that those harboring the APOE4 variant exhibited excessive neuronal firing in the hippocampus—a key region for memory processing. These findings parallel earlier studies that unearthed hyperactivity in the same hippocampal regions among human APOE4 carriers.

Researcher Dennis Tabuena, PhD, noted, "The extent of hyperactivity in young mice predicted how poorly they performed on spatial learning and memory tests later in life." Such predictive power underscores the potential of early intervention strategies.

In comparing APOE4 and APOE3 mice—where the latter variant is associated with a lower risk for Alzheimer’s—the size of hippocampal neurons differed markedly. Neurons in APOE4 mice were diminished in size and more reactive to stimulation, leading to excessive firings. Intriguingly, neurons from APOE3 mice did not exhibit similar excitability until much later in life, suggesting that APOE4 speeds up changes typically linked to natural aging, thus increasing early Alzheimer's susceptibility.

Traditionally, astrocytes—supportive cells in the brain—were thought to play a pivotal role due to their significant production of APOE4. However, the new data indicate that the hyperactivity rooted in APOE4 originates directly from neurons. Zilberter explained, "When we deleted the APOE4 gene from astrocytes, nothing changed. But when we deleted it from neurons, the cells became larger and started functioning normally again."

Research focused on the cellular mechanics of APOE4 revealed higher levels of Nell2 in affecting neuronal populations. This prompted an exploration into reducing Nell2 levels through CRISPR interference techniques in the hippocampi of adult APOE4 mice. The results were revealing: lowered Nell2 resulted in larger, less excitable neurons, underscoring Nell2's role in the excessive neuronal activity characteristic of APOE4 carriers.

This focus on Nell2 is particularly novel; while previous studies linked elevated levels of the protein to Alzheimer's patients’ brains and associated it with cognitive decline, this is its first explicit connection to the APOE4 variant. Huang emphasized the study's implications: "What’s exciting about Nell2 is that we were able to reverse the disease manifestations in adult mice by lowering its level. That tells us the damage is not irreversible and that there may be a window for intervention even after disease processes have been triggered."

Support for the research came from various National Institutes, highlighting the importance of continued investigation in Alzheimer’s research. As scientists deepen their understanding of molecular influences like Nell2 in Alzheimer’s, the path toward effective interventions begins to take shape, potentially transforming the prospects for individuals at risk due to genetic predispositions.